189 related articles for article (PubMed ID: 22884153)
1. Different effects of telmisartan and valsartan on human aortic vascular smooth muscle cell proliferation.
Wang L; Zhao L; Zhang D; Chen JZ; Xue JL
Chin Med J (Engl); 2012 Jun; 125(12):2200-4. PubMed ID: 22884153
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?
Benson SC; Iguchi R; Ho CI; Yamamoto K; Kurtz TW
J Hypertens; 2008 May; 26(5):973-80. PubMed ID: 18398340
[TBL] [Abstract][Full Text] [Related]
3. Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARγ activation.
Chen HY; Xu Z; Chen LF; Wang W; Fang Q; Yan XW
J Cardiovasc Pharmacol; 2012 Jun; 59(6):570-5. PubMed ID: 22392065
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
6. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice.
Ushijima K; Takuma M; Ando H; Ishikawa-Kobayashi E; Nozawa M; Maekawa T; Shiga T; Fujimura A
Eur J Pharmacol; 2013 Jan; 698(1-3):505-10. PubMed ID: 23195328
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma.
Yao Y; Zou R; Liu X; Jiang J; Huang Q; He Y; Li M; Wang S; Zhou J; Ma D; Xu G
J Huazhong Univ Sci Technolog Med Sci; 2008 Oct; 28(5):543-8. PubMed ID: 18846335
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin inhibition stimulates PPARgamma and the release of visfatin.
Storka A; Vojtassakova E; Mueller M; Kapiotis S; Haider DG; Jungbauer A; Wolzt M
Eur J Clin Invest; 2008 Nov; 38(11):820-6. PubMed ID: 19021699
[TBL] [Abstract][Full Text] [Related]
9. Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients.
Miura M; Satoh S; Kagaya H; Saito M; Inoue T; Ohkubo T; Habuchi T; Suzuki T
J Clin Pharm Ther; 2009 Dec; 34(6):683-92. PubMed ID: 20175802
[TBL] [Abstract][Full Text] [Related]
10. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
[TBL] [Abstract][Full Text] [Related]
11. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker.
Kajiya T; Ho C; Wang J; Vilardi R; Kurtz TW
J Hypertens; 2011 Dec; 29(12):2476-83. PubMed ID: 21986624
[TBL] [Abstract][Full Text] [Related]
12. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Nenicu A; Körbel C; Gu Y; Menger MD; Laschke MW
Hum Reprod; 2014 May; 29(5):1011-24. PubMed ID: 24578472
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway.
Sugimoto K; Kazdová L; Qi NR; Hyakukoku M; Kren V; Simáková M; Zídek V; Kurtz TW; Pravenec M
J Hypertens; 2008 Jun; 26(6):1209-15. PubMed ID: 18475159
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats.
Takai S; Jin D; Kimura M; Kirimura K; Sakonjo H; Tanaka K; Miyazaki M
Hypertens Res; 2007 Dec; 30(12):1231-7. PubMed ID: 18344629
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan modulates mitochondrial function in vascular smooth muscle cells.
Takeuchi K; Yamamoto K; Ohishi M; Takeshita H; Hongyo K; Kawai T; Takeda M; Kamide K; Kurtz TW; Rakugi H
Hypertens Res; 2013 May; 36(5):433-9. PubMed ID: 23254392
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
Nakano A; Hattori Y; Aoki C; Jojima T; Kasai K
Hypertens Res; 2009 Sep; 32(9):765-9. PubMed ID: 19590508
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
Tian Q; Miyazaki R; Ichiki T; Imayama I; Inanaga K; Ohtsubo H; Yano K; Takeda K; Sunagawa K
Hypertension; 2009 May; 53(5):798-804. PubMed ID: 19289654
[TBL] [Abstract][Full Text] [Related]
18. [Angiotensin II activates large-conductance Ca(2+)-activated potassium channels in human mesenteric artery smooth muscle cells].
Wen J; Cheng J; Li PY; Mao L; Yue XL; Li C; Yang Y
Sheng Li Xue Bao; 2013 Feb; 65(1):39-46. PubMed ID: 23426512
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan is a potent target for prevention and treatment in human prostate cancer.
Funao K; Matsuyama M; Kawahito Y; Sano H; Chargui J; Touraine JL; Nakatani T; Yoshimura R
Oncol Rep; 2008 Aug; 20(2):295-300. PubMed ID: 18636189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
